2021 Q3: Markets Continue to Shine
- Despite headwinds from an uptick in COVID-19 cases due to the surge of the delta variant, the third quarter continued 2021’s trend of robust M&A activity and strong public equity performance across sectors. Investors in both the private and public markets remain bullish, with early Q4 signs indicating that strong performance will continue, ending the year on a high note.
- Total announced M&A transactions in Q3 took a slight step back from Q2’s record highs, but remained strong, up 17% over Q3 of 2020, and 21% from 2020’s quarterly average. With potential changes to capital gains tax rates still a possibility, business owners continue to aggressively seek to pursue sale transactions. This, paired with significant acquisition interest from both private equity investors as well as strategic acquirers has led to both the active transaction market as well as attractive valuations for sellers across sectors.
- During the year to date, PMCF’s four Medical Technology indices have all seen solid growth, though they were buffeted by a market wide sell-off at the end of the third quarter. Cardiovascular Medical Devices was the strongest performing sector through three quarters, up 12.8% on the year, just above the Dow Jones Industrial Average, which closed up 12.0% and behind the benchmark S&P 500 Growth Index which finished up 17.6%.
Read Medical Technology M&A Pulse Q3 2021 Full Report
Medical Technology M&A Pulse – Q2 2024
Ongoing volatility in the Medical Technology M&A sector is driving heightened diligence and investor scrutiny to ensure acquisition targets are high-quality assets capable of withstanding current market turbulence.
Medical Technology M&A Pulse – Q1 2024
Persistent inflation in Q1 2024 delayed expected rate cuts as the Federal Reserve back tracked expectations from four to three cuts this year.
Medical Technology M&A Pulse – Q4 2023
Concerns about a recession dominated economic discussions in early 2023, fueled by the Federal Reserve’s aggressive response to historically high inflation.
Medical Technology M&A Pulse – Q3 2023
Inflation, while still an economic focal point, is not the sentiment driver it was earlier in the year and in 2022.
Medical Technology M&A Pulse – Q2 2023
One year into an unprecedented cycle of interest rate increases, the task of an economic soft landing, once deemed nearly impossible, appears more and more likely.